Medical management of heavy menstrual bleeding: A comprehensive review of the literature

Obstetrical and Gynecological Survey

Volumn 70, Issue 2, 2015, Pages 115-130

  Bitzer, Johannes ^a   Heikinheimo, Oskari ^b   Nelson, Anita L ^c   Calaf Alsina, Joaquin ^d   Fraser, Ian S ^e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; CENTCHROMAN; CONTRACEPTIVE AGENT; DANAZOL; DESMOPRESSIN; ETAMSYLATE; GESTAGEN; GESTRINONE; LEUPRORELIN; LEVONORGESTREL; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; TRANEXAMIC ACID; ULIPRISTAL; ANTIFIBRINOLYTIC AGENT; ORAL CONTRACEPTIVE AGENT;

ADENOMYOSIS; ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EMBASE; ENDOMETRIAL DISEASE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; LEIOMYOMA; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LUTEAL PHASE; MEDLINE; MENORRHAGIA; MENSTRUAL CYCLE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; VAGINA CONTRACEPTION; VAGINA RING; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; PROGESTINS; TRANEXAMIC ACID;

EID: 84923557709     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000155     Document Type: Article

References (144)

1. Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45:320-351.
2. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol. 2004;190:1224-1229.
3. National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding clinical guideline, January 2007. Commissioned by the National Institute for Health and Clinical Excellence. Available at: http://wwwniceorguk/nicemedia/ pdf/CG44FullGuidelinepdf. Accessed February 4, 2011.
4. Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10:183-194.
5. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013;22:378-384.
6. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271-278.
7. Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disordersinwomen with menorrhagia. Obstet Gynecol. 2005;105:61-66.
8. Cote I, Jacobs P, Cumming DC. Use of health services associated with increased menstrual loss in the United States. Am J Obstet Gynecol. 2003;188:343-348.
9. Jensen JT, Lefebvre P, Laliberte F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt). 2012;21:539-547.
10. Copher R, Nestour EL, Zampaglione E, et al. Heavy menstrual bleeding treatment patterns and associated health care utilization and costs. J Clin Outcomes Manag. 2012;19:402-413.
11. Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100:683-687.
12. Woolcock JG, Critchley HO, Munro MG, et al. Reviewofthecon-fusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril. 2008;90:2269-2280.
13. Fraser IS, Critchley HO, Munro MG, et al. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22:635-643.
14. Fraser IS, Critchley HO, Munro MG. Abnormal uterine bleeding: getting our terminology straight. Curr Opin Obstet Gynecol. 2007;19:591-595.
15. Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3-13.
16. Lieng M, Istre O, Sandvik L, et al. Prevalence, 1-year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study. J Minim Invasive Gynecol. 2009;16:465-471.
17. Anonymous. An evidence-based guideline for the management of heavy menstrual bleeding. Working Party for Guidelines for the Management of Heavy Menstrual Bleeding. N Z Med J. 1999;112:174-177.
18. Hurskainen R, Grenman S, Komi I, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand. 2007;86:749-757.
19. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152:133-137.
20. Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med. 2006; 19: 590-602.
21. ACOG. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72:263-271.
22. Vilos GA, Lefebvre G, Graves GR. Guidelines for the management of abnormal uterine bleeding. J Obstet Gynaecol Can. 2001;23:704-709.
23. Wheeler TL, Murphy M, Rogers RG, et al. Clinical practice guideline for abnormal uterine bleeding: hysterectomy versus alternative therapy. J Minim Invasive Gynecol. 2012;19:81-88.
24. Sweet MG, Schmidt-Dalton TA, Weiss PM, et al. Evaluation and management of abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2012;85:35-43.
25. Abu Hashim H. Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach. Arch Gynecol Obstet. 2013;287:251-260.
26. Matteson KA, Rahn DD, Wheeler TL II, et al. Nonsurgical management of heavy menstrual bleeding. Obstet Gynecol. 2013;121: 632-643.
27. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004;104:1314-1321.
28. Istre O, Trolle B. Treatment of menorrhagia with the levonorges-trel intrauterine system versus endometrial resection. Fertil Steril. 2001;76:304-309.
29. Kittelsen N, Istre O. A randomized study comparing levonorges-trel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TCRE) in the treatment of menorrhagia: preliminary results. Gynaecol Endosc. 1998;7:61-65.
30. Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception. 2011;83:5-9.
31. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol. 1997;90:257-263.
32. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrha-gia. Br J Obstet Gynaecol. 1998;105:592-598.
33. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001;357:273-277.
34. Soysal M, Soysal S, Ozer S. A randomized controlled trial of levo-norgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol. 2002;124:213-219.
35. Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol. 2003;108:72-74.
36. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112:1121-1125.
37. Abdel Malak K, Shawki O. Managementof menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Gynecol Surg. 2006;3:275-280.
38. Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006;113: 257-263.
39. Shaw RW, Symonds IM, Tamizian O, et al. Randomised comparative trial of thermal balloon ablation and levonorgestrel intra-uterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol. 2007;47:335-340.
40. Kucuk T, Ertan K. Continuous oral or intramuscular medroxypro-gesterone acetate versus the levonorgestrel releasing intrauter-ine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol. 2008;35:57-60.
41. Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intra-uterine system toan oral contraceptiveinwomen with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009; 31:340-347.
42. de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing in-trauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception. 2010;81:226-231.
43. Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:625-632.
44. Ghazizadeh S, Bakhtiari F, Rahmanpour H, et al. A randomized clinical trial to compare levonorgestrel-releasing intrauterine system (Mirena) vs trans-cervical endometrial resection for treatment of menorrhagia. Int J Womens Health. 2011;3:207-211.
45. Shabaan MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83:48-54.
46. Sesti F, Piancatelli R, Pietropolli A, et al. Levonorgestrel-releasing intrauterine system versus laparoscopic supracervical hysterectomy for the treatment of heavy menstrual bleeding: a randomized study. J Womens Health (Larchmt). 2012;21: 851-857.
47. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97:690-694.
48. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing in-trauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164:879-883.
49. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995;51:231-235.
50. Barrington JW, Bowen-Simpkins P. The levonorgestrel intra-uterine system in the management of menorrhagia. Br J Obstet Gynaecol. 1997;104:614-616.
51. Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79:963-969.
52. Gupta B, Mittal S, Misra R, et al. Levonorgestrel-releasing in-trauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2006; 95:261-266.
53. Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrha-gia. Int J Gynaecol Obstet. 2007;97:190-194.
54. Gorgen H, Api M, Akca A, et al. Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009;279:835-840.
55. Chattopdhyay B, Nigam A, Goswami S, et al. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011;15:764-768.
56. Kriplani A, Awasthi D, Kulshrestha V, et al. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116:35-38.
57. Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79:1194-1198.
58. Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67: 277-280.
59. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menor-rhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59:29-35.
60. Murat Naki M, Tekcan C, Ozcan N, et al. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94:371-374.
61. Shawki O, El-Sherbiny W, Saber W, et al. Treatment of heavy menstrual bleeding associated with uterine leiomyoma with the levonorgestrel-releasing intrauterine system. Gynecol Surg. 2009;6:331-337.
62. Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynecol Obstet. 2011;112:126-130.
63. Socolov D, Blidaru I, Tamba B, et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care. 2011;16:480-487.
64. Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel-IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai. 2006;89(suppl 4):S147-S151.
65. Xie ZW, Zhang YN, Wan S, et al. Levonorgestrel-releasing intrauterine device is an efficacious contraceptive for women with leiomyoma. J Int Med Res. 2012;40:1966-1972.
66. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68:426-429.
67. Cho S, Nam A, Kim H, et al. Clinical effects ofthe levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol. 2008;198:373.e1-373.e7.
68. Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004; 111: 1425-1428.
69. Choudry A, Malik A, Choudry H, et al. Effectiveness and safety of levonorgestrel releasing intrauterine system in treatment of menorrhagia secondary to oral anticoagulations and chronic liver disease. Rawal Med J. 2009;34:187-190.
70. Kilic S, Yuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception. 2009;80:152-157.
71. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987;34:99-110.
72. Bergqvist A, Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. Br J Obstet Gynaecol. 1983;90: 255-258.
73. Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001;6:93-101.
74. Andrade A, Wildemeersch D. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS. Contraception. 2009; 79:134-138.
75. Wildemeersch D, Rowe PJ. Assessment of menstrual blood loss in women with ideopathic menorrhagia using the frameless levonorgestrel-releasing intrauterine system. Contraception. 2004;70:165-168.
76. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "framelesslntrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2002;102:74-79.
77. Mawet M, Nollevaux F, Nizet D, et al. Impact of a new levonorgestrel intrauterine system, Levosert®, on heavy menstrual bleeding: results of a one-year randomised controlled trial. Eur J Contracept Reprod Health Care. 2014; 19:169-179.
78. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N ZJ Obstet Gynaecol. 1991 ;31:66-70.
79. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind phase III trial. Hum Reprod. 2011 ;26:2698-2708.
80. Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117: 777-787.
81. Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception. 2012;85: 246-252.
82. Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46:327-334.
83. Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16:258-269.
84. Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2010:CD003552.
85. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142, 475 women-years of observation. Contraception. 2007;75:344-354.
86. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143: 697-706.
87. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care. 2010;36:33-38.
88. Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamix acid. Acta Obstet Gynecol Scand. 1967;46:572-580.
89. Freeman EW, Lukes A, Van Drie D, et al.A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011;205.
90. Edlund M, Andersson K, Rybo G, et al. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol. 1995;102:913-917.
91. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone inthe treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102:401-406.
92. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006;26:673-678.
93. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:865-875.
94. Najam R, Agarwal D, Tyagi R, et al. Comparison of tranexamic acid with a combination of tranexamic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). J Clin Diagn Res. 2010;4:3020-3025.
95. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67:645-648.
96. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313:579-582.
97. Srinil S, Jaisamrarn U. Treatment of idiopathic menorrhagia with tranexamic acid. J Med Assoc Thai. 2005;88(suppl 2):S1-S6.
98. Gleeson NC, Buggy F, Sheppard BL, et al. The effect of tranexamic acidon measured menstrual loss and endometrial fi-brinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand. 1994;73:274-277.
99. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145:212-220.
100. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86:714-715.
101. Sundstrom A, Seaman H, Kieler H, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia:a case-control study using the General Practice Research Database. BJOG. 2009; 116:91-97.
102. Sanofi-Synthelabo Australia Pty Limited. Product information: Danocrine. Available at: http://wwwhemingwaysorg/GIDinfo/ drugdata/danocrinepdf. Accessed May 3, 2013.
103. Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980; 87: 1152-1158.
104. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96:840-844.
105. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993;169:1134-1139.
106. Dunphy BC, Goerzen J, Greene CA, et al. A double-blind randomised study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia. J Obstet Gynaecol. 1998;18:553-555.
107. Chimbira TH, Anderson AB, Cope E, et al. Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with menorrhagia. Br J Obstet Gynaecol. 1980;87:330-336.
108. Chimbira TH, Cope E, Anderson AB, et al. The effect of danazol on menorrhagia, coagulation mechanisms, haematological indices and body weight. Br J Obstet Gynaecol. 1979;86:46-50.
109. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990;30:353-356.
110. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol. 1990;76:85-88.
111. Shravage J, Mekhala D, Bellad MB, et al. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: a double-blind randomized controlled trial. J S Asian Fed Obstet Gynecol. 2011;3:21-24.
112. Fraser IS, Pearse C, Shearman RP, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol. 1981;58:543-551.
113. Muggeridge J, Elder MG. Mefenamic acid in the treatment of menorrhagia. Res Clin Forums. 1983;5:83-88.
114. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986;93:974-978.
115. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol. 1986; 68:10-12.
116. Hall P, Maclachlan N, Thorn N, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987;94:554-558.
117. Vargyas JM, Campeau JD, Mishell DR Jr. Treatment of menor-rhagia with meclofenamate sodium. Am J Obstet Gynecol. 1987;157:944-950.
118. Tsang BK, Domingo MT, Spence JE, et al. Endometrial prosta-glandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Can J Physiol Pharmacol. 1987;65:2081-2084.
119. Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991;98:707-711.
120. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menor-rhagia. Am J Obstet Gynecol. 1992;166:1419-1428.
121. Anderson AB, Haynes PJ, Guillebaud J, et al. Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors. Lancet. 1976;1:774-776.
122. Haynes PJ, Flint AP, Hodgson H, et al. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. Int J Gynaecol Obstet. 1980;17:567-572.
123. Fraser IS, McCarron G, Markham R, et al. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol. 1983; 61:109-112.
124. Edlund M, Blomback M, Fried G. Desmopressin inthe treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fi-brinolysis. 2002;13:225-231.
125. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002;8:787-793.
126. Rose SS, Faiz A, Miller CH, et al. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia. 2008;14:571-578.
127. Harrison RF, Cambell S. A double-blind trial of ethamsylate in the treatment of primary and intrauterine-device menorrhagia. Lancet. 1976;2:283-285.
128. Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res. 2009;35:746-752.
129. Ragni MV, Jankowitz RC, Jaworski K, et al. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost. 2011;106:641-645.
130. Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49:77-83.
131. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409-420.
132. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421-432.
133. Nilsson L, Rybo G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. Acta Obstet Gynecol Scand. 1965;44:467-473.
134. Turnbull AC, Rees MC. Gestrinone in the treatment of menor-rhagia. Br J Obstet Gynaecol. 1990;97:713-715.
135. Lukes AS, Muse K, Richter HE, et al. Estimating a meaningful reduction inmenstrual blood loss for women with heavy menstrual bleeding. Current Med Res Opin. 26:2673-2678.
136. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorges-trel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol. 2009;49:316-322.
137. Lee SY, Kim MK, Park H, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hy-perplasia in Korean women. J Gynecol Oncol. 2010;21:102-105.
138. Morelli M, Di Cello A, Venturella R, et al. Efficacy of the levonor-gestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecol Endocrinol. 2013; 29:156-159.
139. James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158:124-134.
140. ACOG Committee of Gynecologic Practice. Committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121:891-896.
141. Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108:924-929.
142. Aksu F, Madazli R, Budak E, et al. High-dose medroxypro-gesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol. 1997; 37:228-231.
143. Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013;208:499. e1-499.e5.
144. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding-a double-blind randomized control study. Obstet Gynecol. 1982; 59:285-291.